Aura Biosciences Reports Q2 2026 Results; 20% Workforce Cut & COO Hired

What Happened
Aura Biosciences, Inc. (AURA) filed an 8‑K on August 11, 2026 announcing its quarterly results for the period ended June 30, 2026 and a corporate realignment to focus on ocular oncology. As part of the realignment the company plans to reduce headcount by approximately 20% and expects related cash costs of roughly $2.9 million to $3.2 million, primarily to be paid in Q3 2026. The filing also discloses executive changes: Susan Abu‑Absi, Ph.D. was appointed Chief Operating Officer effective August 10, 2026, and Chief Financial & Business Officer Anthony Gibney will separate effective September 1, 2026 with a subsequent consulting arrangement; Amy Elazzouzi will serve as interim principal financial officer effective September 2, 2026. The company also filed an updated corporate presentation.

Key Details

• Workforce reduction: ~20% of employees; severance benefits available contingent on execution/non‑revocation of release.
• Estimated exit costs: $2.9M–$3.2M, majority expected to be paid in Q3 2026; estimates subject to change.
• COO hire: Susan Abu‑Absi, Ph.D., start date Aug 10, 2026; base salary $520,000; target bonus 45% of base; inducement equity award ~400,000 shares (≈60% option, 40% RSUs) with multi‑year vesting.
• CFO transition: Anthony Gibney separation effective Sept 1, 2026; eligible for nine months’ salary continuation (subject to release), COBRA health support through June 30, 2027 (subject to election), and a consulting agreement through May 31, 2027 that may continue vesting of existing equity awards. Interim principal financial officer: Amy Elazzouzi, effective Sept 2, 2026.

Why It Matters
For investors, the most immediate impacts are the one‑time restructuring charges ($2.9M–$3.2M) expected in Q3 2026 and a shift of resources away from the company’s non‑muscle invasive bladder cancer (NMIBC) program toward ocular oncology. The workforce reduction and program reprioritization are cost‑management steps that could lower ongoing operating expenses but will generate near‑term cash outflows. Executive changes — a new COO with a significant equity inducement and the CFO’s planned departure with consulting support — may affect operational execution and the company’s financial leadership during the transition. The company also furnished its Q2 results press release and an updated investor presentation.